Joel Jean-Mairet Investor

Joel Jean-Mairet is a seasoned life sciences investor and entrepreneur with a track record of regulatory approval for 4 drugs and 5 medical devices. As the co-founder and CEO of Glycart (now Roche), he played a pivotal role in the discovery and early development of GA101/Gazyva, the first-ever Breakthrough Designated Drug approved by the FDA in 2013. With a passion for innovation, Joel has held key leadership roles in various biotech companies and has been recognized for his impactful transactions in the field of life sciences. His expertise and achievements make him a valuable asset in the healthcare industry.

Invests into